Lantern Pharma Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Panna Sharma
- Full Time Employees
- 16
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1920 McKinney Avenue Dallas TX United States of America 75201
- IPO Date
- Jun 11, 2020
- CIK
- 0001763950
- Website
- lanternpharma.com
- Similar Companies
- Business
- Lantern Pharma Inc. (Nasdaq: LTRN) is a clinical-stage biopharmaceutical company that leverages artificial intelligence, machine learning, and genomics through its proprietary RADR platform—incorporating over 200 billion oncology-focused data points—to accelerate precision oncology drug development, rescue failed candidates, and identify responsive patient populations via biomarker-driven approaches; the platform supports drug positioning, combination strategies, and companion diagnostics across solid tumors and blood cancers. Founded in 2013 and headquartered in Dallas, Texas, the company advances a pipeline including LP-300 in Phase 2 trials for non-small cell lung cancer (NSCLC) adenocarcinoma in never-smokers via the Harmonic trial; LP-184 in Phase 1 for solid tumors such as triple-negative breast cancer (TNBC), NSCLC, bladder cancer, pancreatic cancer, glioblastoma, and other central nervous system (CNS) cancers; LP-284 in Phase 1 for non-Hodgkin lymphomas including mantle cell lymphoma and high-grade B-cell lymphoma; and preclinical antibody-drug conjugate (ADC) programs targeting HER2-expressing models with cryptophycin conjugates, alongside STAR-001 through its wholly owned subsidiary Starlight Therapeutics for glioblastoma, brain metastases, atypical teratoid rhabdoid tumors (ATRT), and pediatric CNS cancers with Rare Pediatric Disease Designations. Lantern Pharma operates primarily in the United States with global research collaborations, focusing on genetically defined cancers and limited-treatment indications to reduce development timelines to 2-3 years at $1.0-2.5 million per program versus traditional methods. Recent developments include completion of LP-184 Phase 1a enrollment in September 2025 with a 48% disease control rate in heavily pretreated patients, tumor reductions in DNA damage repair (DDR)-mutated cancers (e.g., CHK2, ATM, BRCA1), and all primary endpoints met; positive FDA Type C meeting outcomes confirming parallel ATRT cohorts, spironolactone combinations, and regulatory paths for Starlight's pediatric CNS program; expansion of LP-284 sites for lymphoma enrollment and preclinical evaluation in autoimmune indications; planned Q1 2026 initiations for pediatric CNS trials, LP-184 Phase 1b/2 in TNBC/NSCLC, and investigator-led bladder cancer trials; plus ongoing partnership discussions for combinations informed by RADR synergies with PARP inhibitors, immunotherapy, and rituximab.
Lantern Pharma Launches ZetaOmics™ — an Autonomous, Intelligent “Computational Biologist” That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer
Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer
Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer
Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC
Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC
Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates
Lantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor
Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor
Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026
Lantern Pharma Unveils Roadmap for withZeta.ai — Industry-First, Multi-Agentic Co-Scientist Featuring Swarm Intelligence and Computational Biology Toolkit with the Launch of ZetaSwarm™ and ZetaOmics™
Lantern Pharma Inc. (LTRN) Discusses Live Demonstration of withZeta.ai AI Platform for Rare Cancer Drug Discovery Transcript
Lantern Pharma Inc. (LTRN) Discusses Live Demonstration of withZeta.ai Platform for AI-Driven Oncology Drug Discovery Transcript
Lantern Pharma's predictBBB.ai Evolves Into a Real-Time Large Quantitative Model (LQM) for Precision Molecular Intelligence — Comprehensive Small Molecule Characterization & Development Analytics Available as a Web Service to Drug Developers Globally
Lantern Pharma to Debut Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific Debut
Emerging Data for Lantern Pharma's Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With No Added Toxicity
Lantern Pharma Launches withZeta.ai — the World's First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22
Lantern Pharma Inc. (LTRN) Shareholder/Analyst Call Transcript
Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare Cancers — 8:30 AM Eastern, April 9, 2026
Lantern Pharma Inc. (LTRN) Q4 2025 Earnings Call Prepared Remarks Transcript
Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates